Who are Adverse Reactions of Botox intramuscularly's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Botox, AbobotulinumtoxinA (ABO), OnabotulinumtoxinA 100 UNT [Botox], Onabotulinumtoxin A, OnabotulinumtoxinA 100 UNT, OnabotulinumtoxinA Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adverse-reactions-of-botox-intramuscularly.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Adverse Reactions of Botox intramuscularly — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adverse Reactions of Botox intramuscularly (Adverse Reactions of Botox intramuscularly) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology.

phase 1 Botulinum toxin SNAP-25 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Adverse Reactions of Botox intramuscularly (Adverse Reactions of Botox intramuscularly) — ASIS Corporation. Botulinum toxin inhibits acetylcholine release at neuromuscular junctions

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adverse Reactions of Botox intramuscularly TARGET	Adverse Reactions of Botox intramuscularly	ASIS Corporation	phase 1	Botulinum toxin	SNAP-25
Botox	ONABOTULINUMTOXINA	Allergan	marketed	Acetylcholine Release Inhibitor [EPC]	SNAP-25	2010-01-01
AbobotulinumtoxinA (ABO)	AbobotulinumtoxinA (ABO)	Hexsel Dermatology Clinic	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 100 UNT [Botox]	OnabotulinumtoxinA 100 UNT [Botox]	Women and Infants Hospital of Rhode Island	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinumtoxin A	Onabotulinumtoxin A	Wake Forest University Health Sciences	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 100 UNT	OnabotulinumtoxinA 100 UNT	University of South Florida	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA Injectable Product	OnabotulinumtoxinA Injectable Product	University of Utah	marketed	Botulinum toxin	SNAP-25 (synaptosomal-associated protein 25)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

Galderma R&D · 2 drugs in this class
Hexsel Dermatology Clinic · 2 drugs in this class
Seoul National University Hospital · 2 drugs in this class
University of Utah · 2 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
EuBiologics Co.,Ltd · 1 drug in this class
Allergan · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Beth Israel Deaconess Medical Center · 1 drug in this class
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adverse Reactions of Botox intramuscularly — Competitive Intelligence Brief. https://druglandscape.com/ci/adverse-reactions-of-botox-intramuscularly. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab